NEW HAVEN, Conn., April 4, 2018 /PRNewswire/ — Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. The financing was led by new investor Nextech Invest, with…
